Initially, Pharmion concentrated its efforts on licensing products in the areas of hematology, oncology and supportive care. The company has in-licensed four products to date: Thalomid, 5-Azacytidine, Refludan, and Innhep. Pharmion went public in November 2003. (NASDAQ:PHRM).
Pharmion
